Zepbound vs Retatrutide
Editorial comparison of Zepbound (tirzepatide) and Retatrutide (retatrutide). Same drug class context, trial-anchored data, no marketing claims.
Side-by-side
| Dimension | Zepbound | Retatrutide |
|---|---|---|
| Generic name | tirzepatide | retatrutide |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA approved | 2023 | — |
| Mechanism | Tirzepatide is a dual incretin agonist: it hits both the GLP-1 receptor (like semaglutide) and the GIP receptor (which semaglutide doesn't). | Where semaglutide hits one receptor and tirzepatide two, retatrutide adds a third: the glucagon receptor. |
| Dosing | Titrated 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg, every 4 weeks. Maintenance 5-15mg weekly depending on tolerability and target weight. | Investigational. Trial dosing is once-weekly subcutaneous injection with gradual titration; final approved doses are not set. |
| Cost | List price ~$1,000-1,300/month. | No commercial price exists. Available only via clinical-trial enrollment. Beware any website selling 'retatrutide' today, it is not a legal product. |
| Pivotal trial result | 20.9% mean body-weight reduction at 72 weeks (15 mg dose) | ~24% mean body-weight reduction at 48 weeks (highest dose, Phase 2) |
Full Zepbound review →
Dual GLP-1/GIP agonist for weight management. ~20% body weight loss in trials — strongest weight-loss drug currently available.
Full Retatrutide review →
Investigational triple agonist (GLP-1 / GIP / glucagon). Phase 3 weight loss approached ~24%, the highest yet. Not FDA-approved; expected 2027.
Frequently asked
Is Zepbound or Retatrutide more effective?+
In their pivotal trials, Zepbound reported 20.9% mean body-weight reduction at 72 weeks (15 mg dose), while Retatrutide reported ~24% mean body-weight reduction at 48 weeks (highest dose, Phase 2). Head-to-head results vary by patient profile, dose tolerated, and adherence — these trial numbers describe averages, not what every individual experiences.
How do Zepbound and Retatrutide compare on cost?+
Zepbound: List price ~$1,000-1,300/month. Lilly's patient assistance program (LillyDirect Self-Pay) offers $399-549/month for self-pay patients depending on dose. Insurance coverage similar pattern to Wegovy. Retatrutide: No commercial price exists. Available only via clinical-trial enrollment. Beware any website selling 'retatrutide' today, it is not a legal product. Real out-of-pocket depends on insurance formulary tier, manufacturer savings programs, and whether a direct-pay channel is available.
Can I switch from Zepbound to Retatrutide?+
Switching between brand-name treatments in the same drug class is common, but the conversion is not always 1:1. Discuss the switch with your prescriber — they'll usually re-titrate dosing rather than substitute equivalent strengths directly.
Are Zepbound and Retatrutide the same drug?+
No. Zepbound (tirzepatide) and Retatrutide (retatrutide) are distinct medications from Eli Lilly and Eli Lilly respectively. They may share a drug class or mechanism but differ in active ingredient, dosing, and approved use.